Brief Title
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
Official Title
Observational Study to Assess Ease of Use, Acceptability and Preference of Norditropin NordiFlex® With NordiFlex PenMate™ in Subjects on Prescribed Growth Hormone Therapy
Brief Summary
This study is conducted in Europe. The aim of this study is to evaluate ease of injection of growth hormone in patients using Norditropin NordiFlex® with NordiFlex PenMate™. Convenience and tolerability of NordiFlex PenMate™ - an automatic injection and a needle hiding device - is also evaluated.
Study Type
Observational
Primary Outcome
The proportion of subjects that find growth hormone injection using Norditropin Nordiflex® with NordiFlex PenMate™ very easy or easy as assessed by patient/parent questionnaire
Secondary Outcome
Ease of teaching how to use Norditropin Nordiflex® with NordiFlex PenMate™ as assessed by nurse questionnaires
Condition
Growth Hormone Disorder
Intervention
NordiFlex PenMateâ„¢
Study Arms / Comparison Groups
PenMate device
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
84
Start Date
January 2007
Completion Date
March 2009
Primary Completion Date
March 2009
Eligibility Criteria
Inclusion Criteria: - After the physician decision has been made to use Norditropin Nordiflex® growth hormone therapy in accordance with the locally approved labelling, any subject is eligible for the study, including newly diagnosed subjects who have never received growth hormone therapy before and subjects who were treated with the other growth hormone products (with exclusion of patients who received previously Norditropin Nordiflex®) and need to be switched to a new product. The selection of the subjects will be at the discretion of the individual physician Exclusion Criteria: - Contraindications to Norditropin® growth hormone therapy - Subjects who have received Norditropin NordiFlex® prior to this study
Gender
All
Ages
N/A - N/A
Accepts Healthy Volunteers
No
Contacts
Global Clinical Registry (GCR, 1452), ,
Location Countries
Germany
Location Countries
Germany
Administrative Informations
NCT ID
NCT01500486
Organization ID
GH-3717
Responsible Party
Sponsor
Study Sponsor
Novo Nordisk A/S
Study Sponsor
Global Clinical Registry (GCR, 1452), Study Director, Novo Nordisk A/S
Verification Date
November 2016